|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.680 USD | +2.97% |
|
+1.40% | +27.09% |
| 06-18 | TransCode Therapeutics, Inc. - Special Call | |
| 06-03 | TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a | MT |
| Market Cap | 8.01M 7M 6.46M 5.95M 11.22M 771M 11.47M 77.22M 30.37M 378M 30.09M 29.43M 1.3B | P/E 2024 |
-0.07x | P/E 2025 | -0.13x |
|---|---|---|---|---|---|
| Enterprise Value | -9.8M -8.57M -7.9M -7.29M -13.73M -944M -14.04M -94.48M -37.16M -462M -36.81M -36.01M -1.59B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
91.1% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: TransCode Therapeutics, Inc.
| 1 day | +2.97% | ||
| 1 week | +1.40% | ||
| Current month | +39.77% | ||
| 1 month | +73.60% | ||
| 3 months | -2.31% | ||
| 6 months | -0.69% | ||
| Current year | +27.09% |
| 1 week | 8.01 |  | 9.4 |
| 1 month | 4.07 | | 10.69 |
| Current year | 3.82 | | 12.6 |
| 1 year | 3.82 | | 20.99 |
| 3 years | 3.82 | | 118,271.9 |
| 5 years | 3.82 | | 1,000,000 |
| 10 years | 3.82 | | 1,000,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Calais
CEO | Chief Executive Officer | 67 | 2025-10-05 |
Zdravka Medarova
CTO | Chief Tech/Sci/R&D Officer | 52 | 2021-09-30 |
| Chief Executive Officer | 75 | 2024-01-12 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2018-06-30 | |
Philippe Calais
CHM | Chairman | 67 | 2021-02-17 |
Erik Manting
BRD | Director/Board Member | 54 | 2020-12-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/14/24 | Free | Chief Executive Officer | 70,000 | 1.0654% | ||
| 6/14/24 | Free | Chief Financial Officer | 650,000 | 9.8934% | ||
| 6/14/24 | Free | Director | 70,000 | 1.0654% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.97% | +1.40% | -10.42% | -99.99% | 8.01M | |
| +0.40% | -0.61% | +56.31% | +57.69% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.70% | 52.1B | |
| -0.21% | +0.04% | +6.23% | +412.85% | 23.48B | |
| -0.29% | +1.63% | -15.95% | -15.02% | 23.13B | |
| +3.46% | +2.52% | +36.64% | -5.41% | 19.36B | |
| -0.76% | -1.89% | +34.21% | -32.56% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +291.24% | 15.2B | |
| +3.62% | 0.00% | +33.47% | +643.91% | 14.83B | |
| +0.16% | +0.46% | +27.20% | +183.34% | 14.06B | |
| Average | -0.32% | -2.81% | +37.89% | +150.97% | 23.36B | |
| Weighted average by Cap. | -1.44% | -2.36% | +41.89% | +137.72% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -16.75M -14.64M -13.51M -12.45M -23.47M -1.61B -23.99M -161M -63.52M -790M -62.92M -61.54M -2.72B | -34.66M -30.29M -27.95M -25.76M -48.56M -3.34B -49.64M -334M -131M -1.63B -130M -127M -5.63B |
| Net Debt | -5.77M -5.04M -4.66M -4.29M -8.09M -556M -8.27M -55.64M -21.89M -272M -21.68M -21.2M -937M | -17.81M -15.57M -14.37M -13.24M -24.96M -1.72B -25.51M -172M -67.53M -840M -66.9M -65.43M -2.89B |
Employees
12
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-20 | US$8.680 | +2.97% | 502 |
| 26-07-17 | US$8.430 | +1.93% | 5,860 |
| 26-07-16 | US$8.270 | -4.89% | 6,423 |
| 26-07-15 | US$8.695 | +1.34% | 17,711 |
| 26-07-14 | US$8.580 | +0.23% | 17,232 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- RNAZ Stock
Select your edition
All financial news and data tailored to specific country editions
